Étiquette : delta-9 THC

Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans : A Pharmacokinetic Study in Healthy Subjects, Jose A.S. Crippa et al., 2020

Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans : A Pharmacokinetic Study in Healthy Subjects José Alexandre S. Crippa, Antonio Waldo Zuardi, Jaime Eduardo Cecílio Hallak, Bruna Miyazawa, Sandra Aparecido Bernardo, Carmem Maria Donaduzzi, Silvane Guzzi, Wagner Alex Jann Favreto, Alline Campos, Maria Eugênia C. Queiroz, Francisco S. Guimarães, Patrícia Moura da Rosa Zimmermann, Letícia Mello Rechia, Volnei Jose Tondo Filho Cannabis and Cannabinoid Research, 2020, Vol. 5, No. 1 Doi : 10.1089/can.2019.0024 Abstract Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and Methods: Thus, we tested the plasma samples of 120 healthy human subjects [...]

Lire la suite

Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells: Different Mechanisms of THC, CBD, and CB83, Daniela Cerretani et al., 2020

Cytotoxic Effects of Cannabinoids on Human HT-29 Colorectal Adenocarcinoma Cells : Different Mechanisms of THC, CBD, and CB83 Daniela Cerretani, Giulia Collodel, Antonella Brizzi, Anna Ida Fiaschi, Andrea Menchiari, Elena Moretti, Laura Moltoni, Lucia Micheli International Journal of Molecular Sciences, 2020, 21, 5533 Doi : 10.3390/ijms21155533   Abstract In this study, we investigated the effects of exposition to IC50 dose for 24 h of a new synthetic cannabinoid (CB83) and of phytocannabinoids Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on HT-29 colorectal carcinoma cells. Cell viability and proliferative activity evaluated using the MTT, lactate dehydrogenase (LDH), and CyQUANT assays showed that cell viability was significantly affected when CB83, THC, and CBD [...]

Lire la suite

Medicinal use of cannabis based products and cannabinoids, Tom P Freeman et al., 2019

Medicinal use of cannabis based products and cannabinoids Tom P. Freeman, Chandni Hindocha, Sebastian F. Green, Michael A. P. Bloomfield British Medical Journal, 2019, 365, l1141 doi : 10.1136/bmj.l1141   What you need to know • Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for medicinal use typically mimic the effects of specific cannabinoids such as THC • THC is the constituent of cannabis that causes the “high,” whereas CBD is not intoxicating at typical doses. THC and CBD have contrasting mechanisms of action and therapeutic indications; THC [...]

Lire la suite

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats, Leonardo B.M. Resstel et al., 2009

5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats Leonardo B.M. Resstel, Rodrigo F. Tavares, Sabrina F.S. Lisboa, Sâmia R.L. Joca, Fernando M.A. Corrêa and Francisco S. Guimarães British Journal of Pharmacology, 2009, 156, 181–188; doi : 10.1111/j.1476-5381.2008.00046.x Background and purpose : Cannabidiol (CBD) is a non-psychotomimetic compound from Cannabis sativa which induces anxiolytic- and antipsychotic-like effects in rodents. These effects could be mediated by facilitation of the endocannabinoid system or by the activation of 5-HT1A receptors. As either of these mechanisms could promote adaptation to inescapable stress, the aim of the present work [...]

Lire la suite

Do medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers?, Sharon R. Sznitman et al., 2019,

Do medical cannabis growers attempt to produce cannabis with different cannabinoid concentrations than recreational growers? Sharon R. Sznitman, Monica J. Barratt, Tom Decorte, Pekka Hakkarainen, Simon Lenton, Gary Potter, Bernd Werse and Chris Wilkins Drugs and Alcohol Today, 2019, 19, (4), 251-256, Doi : 10.1108/DAT-06-2019-0021   Abstract Purpose – It is conceivable that cannabis cultivators who grow for medical purposes aim to improve the therapeutic index of their cannabis by attempting to produce particular concentrations of CBD and/or THC. The purpose of this paper is to examine whether small-scalemedical cannabis growers differ fromthose growing for recreational reasons in terms of self-assessed concentrations of THC and CBD [...]

Lire la suite

Related Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study, Francesco Patti et al., 2020

Related Symptoms in People With Multiple Sclerosis : Results From a Retrospective Multicenter Study Francesco Patti, Clara Grazia Chisari, Claudio Solaro,  Maria Donata Benedetti , Eliana Berra , Assunta Bianco, Roberto Bruno Bossio, Fabio Buttari, Letizia Castelli, Paola Cavalla , Raffaella Cerqua, Gianfranco Costantino, Claudio Gasperini, Angelica Guareschi, Domenico Ippolito, Roberta Lanzillo, Giorgia Teresa Maniscalco, Manuela Matta, Damiano Paolicelli, Loredana Petrucci, Simona Pontecorvo, Isabella Righini, Margherita Russo, Francesco Saccà, Giovanna Salamone, Elisabetta Signoriello, Gabriella Spinicci, Daniele Spitaleri, Eleonora Tavazzi, Maria Trotta, Mauro Zaffaroni, Mario Zappia, SA.FE. group Doi : 10.1007/s10072-020-04413-6 Abstract Introduction : The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed [...]

Lire la suite

Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury, Jérémie Joffre et al., 2020,

Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury Jérémie Joffre, Che-Chung Yeh, Erika Wong, Mayuri Thete, Fengyun Xu, Ivana Zlatanova, Elliot Lloyd, Lester Kobzik, Matthieu Legrand, and Judith Hellman The Journal of Immunology, 2020, 204: 1–20. doi : 10.4049/jimmunol.2000213   Cannabis sativa and its principal components, D9-tetrahydrocannabinol (D9-THC) and cannabidiol, are increasingly being used to treat a variety of medical problems, including inflammatory conditions. Although studies suggest that the endocannabinoid system has immunomodulatory properties, there remains a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection and injury. [...]

Lire la suite

Developing Robust Standardised Analytical Procedures for Cannabinoid Quantification : Laying the Foundations for an Emerging Cannabis-Based Pharmaceutical Industry, Matthew T. Welling et al., 2019

Developing Robust Standardised Analytical Procedures for Cannabinoid Quantification : Laying the Foundations for an Emerging Cannabis-Based Pharmaceutical Industry Matthew T. Welling, Lei Liu, Arno Hazekamp, Ashley Dowell, Graham J. King Medical Cannabis & Cannabinoids, 2019, 2, 1–13 Doi : 10.1159/000496868   Abstract The plant genus Cannabis is a prolific producer of unique pharmaceutically relevant metabolites, commonly referred to as cannabinoids. Robust and standardised methods for the quantification of cannabinoids within botanical and drug forms is a critical step forward for an emerging Cannabis- based pharmaceutical industry, which is poised for rapid expansion. Despite a growing body of analytical methods for the quantification of cannabinoids, few have [...]

Lire la suite

Effect of D-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults, Anthony N. Nicholson et al., 2004

Effect of D-9-Tetrahydrocannabinol and Cannabidiol on Nocturnal Sleep and Early-Morning Behavior in Young Adults Anthony N. Nicholson, MD, PhD, Claire Turner, BSc, Barbara M. Stone, PhD, and Philip J. Robson, MDy Journal of Clinical Psychopharmacology, 2004, Volume 24, Number 3, 305-313. Doi : 10.1097/01.jcp.0000125688.05091.8f   Abstract : The effects of cannabis extracts on nocturnal sleep, earlymorning performance, memory, and sleepiness were studied in 8 healthy volunteers (4 males, 4 females; 21 to 34 years). The study was double-blind and placebo-controlled with a 4-way crossover design. The 4 treatments were placebo, 15 mg D-9-tetrahydro-cannabinol (THC), 5 mg THC combined with 5 mg cannabidiol (CBD), and 15 mg [...]

Lire la suite

Plant cannabinoids : a neglected pharmacological treasure trove, Raphael Mechoulam, 2005

Plant cannabinoids : a neglected pharmacological treasure trove Raphael Mechoulam British Journal of Pharmacology, 2005, 146, 913–915 doi : 10.1038/sj.bjp.0706415 Most of the cannabinoids in Cannabis sativa L. have not been fully evaluated for their pharmacological activity. A publication in this issue presents evidence that a plant cannabinoid, D9-tetrahydro-cannabivarin is a potent antagonist of anandamide, a major endogenous cannabinoid. It seems possible that many of the non-psychoactive constituents of this plant will be of biological interest. Keywords : Anandamide; CB1 receptor antagonist; CB2 receptor antagonist; mouse vas deferens; D9 tetrahydrocannabinol; D9-tetrahydrocannabivarin; -(þ)-(R)- WIN55212   Cannabis sativa L. produces more than 60 terpeno-phenols that have not been detected [...]

Lire la suite